Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6


A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer.

Michael M, Bang YJ, Park YS, Kang YK, Kim TM, Hamid O, Thornton D, Tate SC, Raddad E, Tie J.

Target Oncol. 2017 Aug;12(4):463-474. doi: 10.1007/s11523-017-0502-9.


A Population Pharmacokinetic and Pharmacodynamic Analysis of Abemaciclib in a Phase I Clinical Trial in Cancer Patients.

Tate SC, Sykes AK, Kulanthaivel P, Chan EM, Turner PK, Cronier DM.

Clin Pharmacokinet. 2018 Mar;57(3):335-344. doi: 10.1007/s40262-017-0559-8.


Early change in tumour size predicts overall survival in patients with first-line metastatic breast cancer.

Tate SC, Andre V, Enas N, Ribba B, Gueorguieva I.

Eur J Cancer. 2016 Oct;66:95-103. doi: 10.1016/j.ejca.2016.07.009. Epub 2016 Aug 18.


Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours.

Tate SC, Burke TF, Hartman D, Kulanthaivel P, Beckmann RP, Cronier DM.

Br J Cancer. 2016 Mar 15;114(6):669-79. doi: 10.1038/bjc.2016.40.


Semi-mechanistic pharmacokinetic/pharmacodynamic modeling of the antitumor activity of LY2835219, a new cyclin-dependent kinase 4/6 inhibitor, in mice bearing human tumor xenografts.

Tate SC, Cai S, Ajamie RT, Burke T, Beckmann RP, Chan EM, De Dios A, Wishart GN, Gelbert LM, Cronier DM.

Clin Cancer Res. 2014 Jul 15;20(14):3763-74. doi: 10.1158/1078-0432.CCR-13-2846. Epub 2014 May 21.


Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data.

Jones HM, Barton HA, Lai Y, Bi YA, Kimoto E, Kempshall S, Tate SC, El-Kattan A, Houston JB, Galetin A, Fenner KS.

Drug Metab Dispos. 2012 May;40(5):1007-17. doi: 10.1124/dmd.111.042994. Epub 2012 Feb 16.


Supplemental Content

Support Center